2215 YUKON STREET, VANCOUVER, A1
Investor Presentation
Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635
Annual Report to Security Holders
Reports Full Year 2025 Business Results
Reach Global Settlement of Patent Litigation
AbCellera Biologics Dismisses KPMG as Independent Auditor
Q1
FY 2024
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
S-3ASR
Effectiveness Notice
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Submission Upload
Post-Effective Amendment to Registration Statement
Correspondence